CSIMarket
 


Enanta Pharmaceuticals Inc  (ENTA)
Other Ticker:  
 
 

ENTA's Capital Expenditures Growth by Quarter and Year

Enanta Pharmaceuticals Inc's Capital Expenditures results by quarter and year




ENTA Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter September 1.37 1.44 0.03 0.33
III Quarter June 2.15 0.25 0.40 0.27
II Quarter March 2.38 0.07 0.13 0.35
I Quarter December 3.16 0.36 0.19 0.49
FY   9.06 2.12 0.75 1.44



ENTA Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Enanta Pharmaceuticals Inc reported decrease in Capital Expenditures in the fourth quarter 2023 by -5% to $ 1.37 millions, from the same quarter in 2022.
The decrease in the fourth quarter 2023 Enanta Pharmaceuticals Inc's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 116.56%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Capital Expenditures growth. While Enanta Pharmaceuticals Inc' s Capital Expenditures decline of -5% ranks overall at the positon no. 117 in the fourth quarter 2023.




ENTA Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter September -5 % 4700 % -90.91 % 10 %
III Quarter June 760 % -37.5 % 48.15 % -87.89 %
II Quarter March 3300 % -46.15 % -62.86 % -86.06 %
I Quarter December 777.78 % 89.47 % -61.22 % 28.95 %
FY   327.26 % 182.67 % -47.92 % -73.43 %

Financial Statements
Enanta Pharmaceuticals Inc's fourth quarter 2023 Capital Expenditures $ 1.37 millions ENTA's Income Statement
Enanta Pharmaceuticals Inc's fourth quarter 2022 Capital Expenditures $ 1.44 millions Quarterly ENTA's Income Statement
New: More ENTA's historic Capital Expenditures Growth >>


ENTA Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter September -36.37 % 476 % -92.5 % 22.22 %
III Quarter June -9.66 % 257.14 % 207.69 % -22.86 %
II Quarter March -24.68 % -80.56 % -31.58 % -28.57 %
I Quarter December 119.44 % 1100 % -42.42 % 63.33 %
FY (Year on Year)   327.26 % 182.67 % -47.92 % -73.43 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #15
Healthcare Sector #30
Overall #117

Capital Expenditures Y/Y Growth Statistics
High Average Low
1165.88 % 116.56 % -79.26 %
(Jun 30 2023)   (Dec 31 2020)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #15
Healthcare Sector #30
Overall #117
Capital Expenditures Y/Y Growth Statistics
High Average Low
1165.88 % 116.56 % -79.26 %
(Jun 30 2023)   (Dec 31 2020)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Enanta Pharmaceuticals Inc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1000 % 86.98 % -91.73 %
(Dec 31 2021)  


ENTA's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Enanta Pharmaceuticals Inc disclosed fall in Capital Expenditures from the previous quarter by -36.37% to $ 1.37 millions, from $ 2.15 millions achived in the previous reporting period.

Although periodic influence normally elevate IV. Quarter 2023 Capital Expenditures, it plainly was not sufficient to salvage ENTA's IV. Quarter achievement, Mia Jones, market expert said and continued that average quarter on quarter Capital Expenditures growth is at 86.98% for ENTA.

Within Major Pharmaceutical Preparations industry 144 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Enanta Pharmaceuticals Inc's Capital Expenditures growth quarter on quarter, overall rank is 2596.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #145
Healthcare Sector #404
Overall #2596
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #145
Healthcare Sector #404
Overall #2596
Capital Expenditures Q/Q Growth Statistics
High Average Low
1000 % 86.98 % -91.73 %
(Dec 31 2021)  


ENTA's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Enanta Pharmaceuticals Inc disclosed fall in Capital Expenditures from the third quarter by -36.37% to $ 1.37 millions, from $ 2.15 millions declared in the previous quarter.

Although seasonal factors normally fuel IV. Quarter 2023 Capital Expenditures, it clearly has not been enough to salvage Enanta Pharmaceuticals Inc's outcome, Mia Jones, market expert pointed out and wrote that average quarter on quarter Capital Expenditures growth is at 86.98% for Enanta Pharmaceuticals Inc.

Within Major Pharmaceutical Preparations industry 144 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Enanta Pharmaceuticals Inc's Capital Expenditures growth quarter on quarter, overall rank is 2596.


Enanta Pharmaceuticals Inc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 9.06 $ 9.13 $ 7.23 $ 4.92 $ 2.13
Y / Y Capital Expenditures Growth (TTM) 326.26 % 1165.88 % 731.65 % 431.68 % 183.33 %
Year on Year Capital Expenditures Growth Overall Ranking # 127 # 1972 # 1242 # 1746 # 265
Seqeuential Capital Expenditures Change (TTM) -0.76 % 26.29 % 46.95 % 131.44 % 194.73 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 117 # 1092 # 1247 # 1003 # 54




Cumulative Capital Expenditures growth Comment
Assuming the Enanta Pharmaceuticals Inc's fiscal year would have ended in Sep 30 2023, Enanta Pharmaceuticals Inc would have reprted above average annual Capital Expenditures surge of 326.26% year on year, of $ 9 millions.
This marks a slow-down of the companys growth trends and from the 1165.88% surge in Jun 30 2023.

Within the Healthcare sector 32 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 127, from total ranking in previous quarter at 1972.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1165.88 %
116.56 %
-79.26 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 15
Healthcare Sector # 33
Overall # 127

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1165.88 %
116.56 %
-79.26 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 30
S&P 500 # 117
Cumulative Capital Expenditures growth Comment
Assuming the Enanta Pharmaceuticals Inc's fiscal year would have ended in Sep 30 2023, Enanta Pharmaceuticals Inc would have reprted above average annual Capital Expenditures surge of 326.26% year on year, of $ 9 millions.
This marks a slow-down of the companys growth trends and from the 1165.88% surge in Jun 30 2023.

Within the Healthcare sector 32 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 127, from total ranking in previous quarter at 1972.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1165.88 %
116.56 %
-79.26 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 15
Healthcare Sector # 33
Overall # 127

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1165.88 %
116.56 %
-79.26 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 30
S&P 500 # 117




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ENTA's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ENTA's Competitors
Capital Expenditures Growth for Enanta Pharmaceuticals Inc's Suppliers
Capital Expenditures Growth for ENTA's Customers

You may also want to know
ENTA's Annual Growth Rates ENTA's Profitability Ratios ENTA's Asset Turnover Ratio ENTA's Dividend Growth
ENTA's Roe ENTA's Valuation Ratios ENTA's Financial Strength Ratios ENTA's Dividend Payout Ratio
ENTA's Roa ENTA's Inventory Turnover Ratio ENTA's Growth Rates ENTA's Dividend Comparisons



Companies with similar Capital Expenditures surge for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com